Biosimilar growth hormones market seen reaching $1.46 billion by 2030
The biosimilar growth hormones market is projected to climb from $0.89 billion in 2025 to $1.46 billion by 2030, according to The Business Research Company. Growth is tied to rising growth hormone deficiency diagnoses, patent expirations, broader biosimilar approvals and expanding self-administration options.
Why it matters: - Biosimilar growth hormones offer a lower-cost alternative to branded growth hormone therapies. - Rising diagnoses of growth hormone deficiency are expanding demand for treatment. - Wider use of biosimilars could improve access in both pediatric and adult care.
What happened: - The Business Research Company published its Biosimilar Growth Hormones Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report projects the market will rise from $0.89 billion in 2025 to $0.98 billion in 2026. - The report forecasts the market will reach $1.46 billion by 2030. - The report also projects a 10.5% CAGR through 2030.
The details: - Historical growth has been supported by high branded therapy costs, more diagnoses of pediatric growth disorders, limited access to affordable treatments and hospital-based administration. - The report points to patent expirations on branded growth hormones as a major future driver. - Increased regulatory approvals for biosimilars are expected to add momentum. - Broader availability of self-administration options is another forecasted tailwind. - Growing awareness of growth disorders and higher healthcare spending in emerging markets are also expected to support demand. - The report highlights a shift toward subcutaneous self-administration. - Online pharmacies and specialty clinics are expected to expand distribution. - Improved regulatory acceptance of biosimilar products is listed as a trend. - Biosimilar growth hormones are peptide hormones that support cellular regeneration, division and overall growth. - These hormones play a role in therapeutic treatment for people with hormone deficiencies. - Growth hormone deficiency can result from damage or malfunction of the pituitary gland or hypothalamus and can be congenital or acquired. - Hormones Australia, governed by the Endocrine Society of Australia, reported in September 2023 that GHD affects about 2 to 3 out of every 10,000 people in Australia.
Between the lines: - North America held the largest share of the global market in 2025, helped by advanced healthcare infrastructure and wider biosimilar adoption. - The Middle East is expected to be the fastest-growing region over the forecast period. - The forecast suggests biosimilars are moving from a niche alternative toward broader mainstream use as access and regulatory pathways improve.
What's next: - The market is expected to keep expanding through 2030 as more biosimilar products gain approvals and distribution channels widen. - Demand will likely be shaped by how quickly self-administration and specialty pharmacy models scale. - The report says its 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards, hotspots infographics, and updated graphics and tables. - More information is available in the full report and the sample request.
The bottom line: - Biosimilar growth hormones are on a steady growth path, powered by cost pressure, rising diagnoses and a shift toward more accessible treatment models.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
The Australia Globe
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.